{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"260.9","value":"246.1"}]}],"title":"Cycle 2, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"210.8","value":"227.6"}]}],"title":"Cycle 3, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"357.1","value":"507.1"}]}],"title":"Cycle 3, Day 1 (Post-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"236.1","value":"253.2"}]}],"title":"Cycle 4, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"286.9","value":"257.6"}]}],"title":"Cycle 5, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"225.1","value":"247.8"}]}],"title":"Cycle 6, Day 1 (Pre-dose)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"373"}],"units":"Participants"}],"description":"Individual plasma tucatinib concentrations at each sampling time","dispersionType":"Standard Deviation","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"}],"paramType":"MEAN","populationDescription":"Pharmacokinetics (PK) Analysis Set: Includes all randomized participants who received at least one dose of tucatinib and who had at least one evaluable PK assessment. Participants were evaluated by the treatment actually received.","reportingStatus":"POSTED","timeFrame":"3.5 months","title":"Pharmacokinetic Measure: Ctrough of Tucatinib","type":"SECONDARY","unitOfMeasure":"ng/mL"}